42 related articles for article (PubMed ID: 27739679)
1. From Lead to Drug Candidate: Optimization of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as Agents for the Treatment of Triple Negative Breast Cancer.
Zhang CH; Chen K; Jiao Y; Li LL; Li YP; Zhang RJ; Zheng MW; Zhong L; Huang SZ; Song CL; Lin WT; Yang J; Xiang R; Peng B; Han JH; Lu GW; Wei YQ; Yang SY
J Med Chem; 2016 Nov; 59(21):9788-9805. PubMed ID: 27739679
[TBL] [Abstract][Full Text] [Related]
2. Synthesis, design, and antiproliferative evaluation of 6-(N-Substituted-methyl)pyrazolo[3,4-d]pyrimidines as the potent anti-leukemia agents.
Chung CY; Li SM; Zeng WZ; Uramaru N; Huang GJ; Juang SH; Wong FF
Bioorg Chem; 2024 Jul; 148():107424. PubMed ID: 38728908
[TBL] [Abstract][Full Text] [Related]
3. N- and s-substituted Pyrazolopyrimidines: A promising new class of potent c-Src kinase inhibitors with prominent antitumor activity.
Awaji AA; Zaloa WAZE; Seleem MA; Alswah M; Elsebaei MM; Bayoumi AH; El-Morsy AM; Alfaifi MY; Shati AA; Elbehairi SEI; Almaghrabi M; Aljohani AKB; Ahmed HEA
Bioorg Chem; 2024 Apr; 145():107228. PubMed ID: 38422592
[TBL] [Abstract][Full Text] [Related]
4. The 3-D conformational shape of N-naphthyl-cyclopenta[d]pyrimidines affects their potency as microtubule targeting agents and their antitumor activity.
Xiang W; Quadery TM; Hamel E; Luckett-Chastain LR; Ihnat MA; Mooberry SL; Gangjee A
Bioorg Med Chem; 2021 Jan; 29():115887. PubMed ID: 33310545
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and evaluation of a pyrazolo[3,4-d]pyrimidine derivative as a novel and potent TGFβ1R1 inhibitor.
Wang Y; Liu Y; Zhang Y; Zhang Z; Xu L; Wang J; Yang Y; Hu B; Yao Y; Wei M; Wang J; Tang B; Zhang K; Liu S; Yang G
Eur J Med Chem; 2024 May; 271():116395. PubMed ID: 38626523
[TBL] [Abstract][Full Text] [Related]
6. Design, Synthesis, and Preclinical Evaluation of 4-Substituted-5-methyl-furo[2,3-d]pyrimidines as Microtubule Targeting Agents That Are Effective against Multidrug Resistant Cancer Cells.
Devambatla RK; Namjoshi OA; Choudhary S; Hamel E; Shaffer CV; Rohena CC; Mooberry SL; Gangjee A
J Med Chem; 2016 Jun; 59(12):5752-65. PubMed ID: 27213719
[TBL] [Abstract][Full Text] [Related]
7. Multipathway regulation induced by 4-(phenylsulfonyl)morpholine derivatives against triple-negative breast cancer.
Yang FW; Mai TL; Lin YJ; Chen YC; Kuo SC; Lin CM; Lee MH; Su JC
Arch Pharm (Weinheim); 2024 May; 357(5):e2300435. PubMed ID: 38314850
[TBL] [Abstract][Full Text] [Related]
8. Discovery of acetophenone/piperazin-2-one hybrids as selective anti-TNBC cancer agents by causing DNA damage.
Zhang ZJ; Liao YT; Wang W; Yang C; Li D; Shao LD
Bioorg Med Chem Lett; 2024 Aug; 108():129802. PubMed ID: 38777278
[TBL] [Abstract][Full Text] [Related]
9. Discovery of 5-(Pyrimidin-2-ylamino)-1
Qin J; Niu B; Chen X; Hu C; Lu S; Li H; Liu W; Li J; Teng Z; Yang Y; Hu H; Xu Y; Huo S; Wu Z; Qiu Y; Zhou H; Fang M
J Med Chem; 2023 Dec; 66(23):15847-15866. PubMed ID: 37983615
[TBL] [Abstract][Full Text] [Related]
10. Pyrazolo - Pyrimidines as Targeted Anticancer Scaffolds - A Comprehensive Review.
Kandhasamy K; Surajambika RR; Velayudham PK
Med Chem; 2024; 20(3):293-310. PubMed ID: 37885114
[TBL] [Abstract][Full Text] [Related]
11. Anticancer Properties of Halogenated Pyrrolo[3,2-d]pyrimidines with Decreased Toxicity via N5 Substitution.
Cawrse BM; Lapidus RS; Cooper B; Choi EY; Seley-Radtke KL
ChemMedChem; 2018 Jan; 13(2):178-185. PubMed ID: 29193845
[TBL] [Abstract][Full Text] [Related]
12. RuBi-Ruxolitinib: A Photoreleasable Antitumor JAK Inhibitor.
Rafic E; Ma C; Shih BB; Miller H; Yuste R; Palomero T; Etchenique R
J Am Chem Soc; 2024 May; 146(19):13317-13325. PubMed ID: 38700457
[TBL] [Abstract][Full Text] [Related]
13. Copper-catalyzed synthesis of pyrazolo[1,5-a]pyrimidine based triazole-linked glycohybrids: mechanistic insights and bio-applications.
Tiwari G; Khanna A; Tyagi R; Mishra VK; Narayana C; Sagar R
Sci Rep; 2024 Jan; 14(1):529. PubMed ID: 38177184
[TBL] [Abstract][Full Text] [Related]
14. Total Synthesis of a TNBC-Selective Cytotoxic Bromo Nor-eremophilane, PC-A, and Its Preliminary Structure-Activity Relationships.
Maeda S; Nakayama W; Saito Y; Sagano M; Goto M; Nakagawa-Goto K
J Nat Prod; 2024 Apr; 87(4):861-868. PubMed ID: 38438305
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and Antiproliferative Activity of 2,4,6,7-Tetrasubstituted-2
Razmienė B; Řezníčková E; Dambrauskienė V; Ostruszka R; Kubala M; Žukauskaitė A; Kryštof V; Šačkus A; Arbačiauskienė E
Molecules; 2021 Nov; 26(21):. PubMed ID: 34771163
[TBL] [Abstract][Full Text] [Related]
16. Lead Compound Development of SRC-3 Inhibitors with Improved Pharmacokinetic Properties and Anticancer Efficacy.
Lu D; Chen J; Qin L; Bijou I; Yi P; Li F; Song X; MacKenzie KR; Yu X; Yang B; Roy Chowdhury S; Korp JD; O'Malley BW; Lonard DM; Wang J
J Med Chem; 2024 Apr; 67(7):5333-5350. PubMed ID: 38551814
[TBL] [Abstract][Full Text] [Related]
17. Unprecedented synthesis of a 14-membered hexaazamacrocycle.
Fesenko AA; Shutalev AD
Beilstein J Org Chem; 2023; 19():1728-1740. PubMed ID: 38025087
[TBL] [Abstract][Full Text] [Related]
18. 4-Aminopyrazolopyrimidine scaffold and its deformation in the design of tyrosine and serine/threonine kinase inhibitors in medicinal chemistry.
Chen X; Huang Y; Xu W; Cai Y; Yang Y
RSC Med Chem; 2022 Sep; 13(9):1008-1028. PubMed ID: 36324498
[TBL] [Abstract][Full Text] [Related]
19. Aspirin mediates histone methylation that inhibits inflammation-related stemness gene expression to diminish cancer stemness via COX-independent manner.
Zhang X; Du R; Luo N; Xiang R; Shen W
Stem Cell Res Ther; 2020 Aug; 11(1):370. PubMed ID: 32854760
[TBL] [Abstract][Full Text] [Related]
20. Use of Zebrafish in Drug Discovery Toxicology.
Cassar S; Adatto I; Freeman JL; Gamse JT; Iturria I; Lawrence C; Muriana A; Peterson RT; Van Cruchten S; Zon LI
Chem Res Toxicol; 2020 Jan; 33(1):95-118. PubMed ID: 31625720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
